Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.48 |
| ▸ | RAF1 | P04049 | 4/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | KRAS | P01116 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.40 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.40 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052141 | 0.95 | BRAF (0.47) | BRAFRAF1MAPK14KRASKDR | |
| SCHEMBL5060168 | 0.93 | BRAF (0.46) | BRAFRAF1MAPK14KRASKDR | |
| SCHEMBL5056538 | 0.92 | BRAF (0.42) | BRAFRAF1MAPK14KRASKDR | |
| SCHEMBL5062080 | 0.90 | BRAF (0.45) | BRAFRAF1MAPK14KRASKDR | |
| SCHEMBL5056293 | 0.89 | BRAF (0.44) | BRAFRAF1MAPK14KRASKDR | |
| SCHEMBL5060166 | 0.89 | BRAF (0.51) | BRAFRAF1MAPK14KRASKDR | |
| SCHEMBL5052205 | 0.88 | BRAF (0.43) | BRAFRAF1KRASKDRFGFR1 | |
| SCHEMBL5060258 | 0.87 | BRAF (0.42) | BRAFRAF1MAPK14KRASKDR | |
| SCHEMBL5057477 | 0.86 | BRAF (0.49) | BRAFRAF1MAPK14KRASKDR | |
| SCHEMBL5056310 | 0.85 | BRAF (0.40) | BRAFRAF1MAPK14KRASKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | BRAF 2/4885RAF1 55/4885MAPK14 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.